• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Obrien Geoffrey

    1/11/24 4:52:35 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNOV alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    OBrien Geoffrey

    (Last) (First) (Middle)
    C/O MEDICINOVA, INC.
    4275 EXECUTIVE SQUARE, SUITE 300

    (Street)
    LA JOLLA CA 92037

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    MEDICINOVA INC [ MNOV ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Vice President
    3. Date of Earliest Transaction (Month/Day/Year)
    01/09/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Stock Option (Right to Buy) $2.4 01/09/2024 A 84,000 01/09/2024 01/31/2033 Common Stock 84,000 $0 84,000(1) D
    Explanation of Responses:
    1. On February 1, 2023 the reporting person was granted an option to purchase 120,000 shares of common stock. The option vests based on the satisfaction of certain performance criteria for the fiscal year ended December 31, 2023. Such performance criteria for 2023 were achieved at the 70% attainment level, resulting in vesting of the option as to 84,000 shares.
    /s/ Yuichi Iwaki, attorney-in-fact 01/11/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MNOV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MNOV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MNOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

    LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that as of the end of January 2026, 12 sites in the US are activated and 100 patients have been enrolled in the SEANOBI study (Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS; NCT 06743776) representing 50% of the planned 200-enrollment, evaluating MN‑166 (ibudilast) in patients with amyotrophic lateral sclerosis (ALS). Dr. Yuichi Iwaki, President and CEO of MediciNova, commented: "Achieving 100 enrolled patients in the N

    1/29/26 6:00:00 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    2026 New Year's Greetings from the CEO

    LA JOLLA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) provides shareholders a corporate update in the following Letter to Stockholders from CEO Yuichi Iwaki, M.D., Ph.D. Dear Fellow Shareholders, The year 2025 was marked by global uncertainty, with accelerating inflation, evolving U.S. trade policies under the new administration, and persistent geopolitical risks. Despite these challenges, MediciNova achieved significant milestones, including completion of patient enrollment in three clinical trials and the launch of a large-

    1/6/26 9:00:00 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

    LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient enrollment in the randomized, placebo-controlled Phase 2 clinical trial, the OXTOX study (Oxaliplatin Neurotoxicity study in patients with metastatic colorectal cancer). This study, an investigator-initiated clinical trial led by Dr. Janette Vardy and Dr. Haryana Dhillon, is evaluating MN-166 (ibudilast) for the prevention of chemotherapy-induced peripheral neuropathy in patients with metastatic colorectal cancer. A total

    12/18/25 6:00:00 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNOV
    SEC Filings

    View All

    SEC Form 424B5 filed by Medicinova Inc

    424B5 - MEDICINOVA INC (0001226616) (Filer)

    12/30/25 7:55:04 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Medicinova Inc

    8-K - MEDICINOVA INC (0001226616) (Filer)

    12/30/25 7:53:12 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Medicinova Inc

    EFFECT - MEDICINOVA INC (0001226616) (Filer)

    12/12/25 12:15:16 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Medical Officer Matsuda Kazuko

    4 - MEDICINOVA INC (0001226616) (Issuer)

    1/20/26 5:04:59 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President and CEO Iwaki Yuichi

    4 - MEDICINOVA INC (0001226616) (Issuer)

    1/20/26 5:03:52 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Nagao Hideki

    4 - MEDICINOVA INC (0001226616) (Issuer)

    6/20/25 4:11:47 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on MediciNova with a new price target

    Maxim Group initiated coverage of MediciNova with a rating of Buy and set a new price target of $15.00

    3/16/21 8:15:44 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on MediciNova with a new price target

    Maxim Group initiated coverage of MediciNova with a rating of Buy and set a new price target of $15.00

    3/10/21 7:48:19 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNOV
    Leadership Updates

    Live Leadership Updates

    View All

    MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

    LA JOLLA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), is pleased to announce the appointment of Dr. Christopher D. Breder, MD, PhD as Clinical and Regulatory Advisor. Dr. Breder will provide strategic guidance for MediciNova's Drug Development programs and will lead the Scientific Advisory Board upon its formation. Dr. Christopher D. Breder, MD, PhD, is a distinguished physician-scientist and regulatory expert with over two decades of experience across the U.S. Food and Drug Administration (FDA) and major pharmaceutical compa

    11/18/25 6:00:00 AM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Medicinova Inc (Amendment)

    SC 13D/A - MEDICINOVA INC (0001226616) (Subject)

    7/12/22 12:12:02 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care